Reduction of fibroproliferative changes in irradiated rat lung with soluble transforming growth factor-β receptor

AKIHITO NISHIOKA¹, YASUHIRO OGAWA¹, SHINJI KARIYA¹, NORIHIKO HAMADA¹, MUNENOBU NOGAMI¹, TAISUKE INOMATA² and HIKARU UENO³

¹Department of Diagnostic Radiology and Radiation Oncology, Kochi University, School of Medicine, Nankoku, Kochi 783-8505; ²Department of Radiation Oncology, Shimane University, Izumo, Shimane 693-8501; ³Department of Biochemistry and Molecular Pathophysiology, University of Occupational and Environmental Health, School of Medicine, Kitakyusyu, Fukuoka 807-8556, Japan

Received November 25, 2013; Accepted June 9, 2014

DOI: 10.3892/mmr.2014.3064

Abstract. The present study investigated whether established fibroproliferative changes in the irradiated rat lung are histopathologically reduced by an adenovirus-mediated soluble transforming growth factor (TGF)-β type II receptor. Replication-defective adenoviral vectors expressing a type II human TGF-β receptor (AdTβ-ExR) were prepared. Male Fisher-344 rats were divided into the C, R and R + T groups. The rats in the C group did not receive irradiation or treatment. The rats in the R and R + T group each received 30 Gy irradiation to the right lung. Eight weeks following irradiation, the rats in the R and R + T group were treated with saline or AdTβ-ExR, respectively. To analyze the TGF-β expression, myofibroblast proliferation and macrophage/microcyte infiltration, sections of the lung were immunohistochemically stained at 16 weeks following irradiation. Silver staining was performed for semi-quantitative evaluation of the fibroproliferative changes. Definitive TGF-β expression, myofibroblast proliferation and macrophage/microcyte infiltration were observed in the lungs of the R group, but were significantly lower in the lungs of the R + T group. With respect to the fibroproliferative changes, the proportion of red-stained areas in the R + T group was markedly lower than that in the R group. These data indicate that fibroproliferative changes induced by radiation are reversible and that TGF-β has a critical role in fibroproliferative changes in the irradiated lung. The present results suggest that gene therapy with an adenoviral vector expressing a soluble TGF-β receptor may be effective in reducing the established pulmonary fibrosis caused by radiation.

Introduction

Radiation-induced pulmonary injuries are important complications of chest irradiation. Clarifying the detailed molecular mechanisms underlying these injuries, and developing effective methods for their prevention and treatment are required for more effective and safer chest irradiation. Fibroproliferative changes resulting in fibrosis are considered to be dynamic and reversible processes involving constant remodeling and long-term fibroblast activation. Fibroproliferative lesions contain infiltrating inflammatory cells, including macrophages/microcytes and specific fibroblasts termed myofibroblasts (1-3).

Transforming growth factor-β (TGF-β) is considered to be a master switch for fibroproliferative changes in irradiated lung tissue (4-6). That is, overexpression or activation of TGF-β for a prolonged period may induce myofibroblast proliferation, macrophage/microcyte infiltration and extracellular matrix deposition, resulting in pulmonary fibrosis (Fig. 1).

Previously, based on the known molecular mechanisms, the ability of adenovirus-mediated soluble TGF-β type II receptor gene therapy to ameliorate active TGF-β expression and prevent radiation-induced pulmonary injury was demonstrated (7). As the next step, using an adenovirus-mediated soluble TGF-β type II receptor, which adsorbs TGF-β and may act as a dominant-negative receptor to inhibit the function of wild-type receptor, the present study investigated whether established fibroproliferative changes in the irradiated lung may be reduced.

Materials and methods

Adenoviral vectors. Replication-defective E1⁻ and E3⁻ adenoviral vectors expressing the entire extracellular domain of the type II human TGF-β receptor fused with the Fc protein of human IgG₁ (AdTβ-ExR), under the control of a CA promoter comprising a cytomegalovirus enhancer and a chicken β-actin promoter, were prepared by in vitro homologous recombination in 293 cells (Kyushu University, Fukuoka, Japan), as described previously (8,9). It was confirmed that the soluble TGF-β type II receptor was secreted from AdTβ-ExR-infected cells and was detectable in circulating blood following AdTβ-ExR
It was also confirmed that the soluble receptor bound to TGF-β and inhibited TGF-β activity in vivo and in vitro (8,9). The titer of the virus stock was assessed by a plaque formation assay using 293 cells and is expressed in plaque-forming units (PFU).

**Animal model.** The present study was conducted under the Guidelines for Animal Experiments of Kochi University, (Kochi, Japan). All of the animals were treated following the procedures approved by the Committee on Animal Research of Kochi University. Male Fisher-344 rats (SLC, Shizuoka, Japan) aged 12 weeks were divided into three groups: An intact control group (C group), a radiation plus saline group (R group) and a radiation plus soluble TGF-β type II receptor group (R + T group). Each group consisted of three rats. The rats in the C group did not receive irradiation or treatment. The rats in the R and R + T groups each received 4-MV X-ray irradiation at a dose of 30 Gy in a single fraction of the right lung using a linear accelerator (ML-15MDX; Mitsubishi Electric Co., Ltd., Tokyo, Japan). Eight weeks following irradiation, the rats in the R and R + T groups were treated with a single infusion of 0.5 ml saline or AdTGF-ExR (1.0x10⁹ PFU/ml), respectively, via the external jugular vein. It was previously reported that marked TGF-β expression, myofibroblast proliferation, macrophage/macrophage infiltration and fibroproliferative changes were observed in the irradiated lungs of rats at 8 weeks following 30 Gy irradiation (7). The rats in all of the groups were housed under the same conditions with ad libitum access to food and water for 16 weeks after irradiation (8 weeks after single infusion). The rats were then sacrificed with an intraperitoneal injection of pentobarbital sodium (2.5 ml/rat) for lung extraction.

**Histopathological examination.** For the histopathological investigation, the right lungs of all of the rats were fixed in 10% neutral-buffered formalin, embedded in paraffin and sectioned (5-μm sections) with a microtome. A number of mounted sections were stained with hematoxylin and eosin (H&E). To analyze TGF-β expression, myofibroblast proliferation and macrophage/macrophage infiltration, other tissue sections of the lung were immunohistochemically stained using the avidin-biotin-horseradish peroxidase complex (ABC) method with anti-TGF-β1 antibody (1:100; Promega Corporation, Madison, WI, USA), anti-α-smooth muscle actin antibody (1:200; DAKO A/S, Copenhagen, Denmark) and anti-CD68 antibody (1:100; KP1 clone; DAKO A/S) as the primary antibodies. Immunoreactive materials were visualized using biotinylated anti-mouse (or anti-rabbit) immunoglobulin G secondary antibody (1:100; Vector Laboratories, Inc., CA, USA), peroxidase-labeled streptavidin (Vector Laboratories, Inc.) and diaminobenzidine (Sigma-Aldrich, St. Louis, MO, USA). Firstly, the sections were incubated in the primary antibodies at the appropriate dilutions for 1 h at room temperature. They were then incubated in peroxidase blocking solution (0.3% H₂O₂) for 10 min and in the biotinylated secondary antibody for 30 min at room temperature. Finally, the sections were incubated in peroxidase-labeled streptavidin for 30 min at room temperature, and then visualized with diaminobenzidine. The number of TGF-β-expressing cells within a field at a magnification of x400 (area, ~240x320 μm) were then counted using a microscope (Eclipse 80i; Nikon Corporation, Tokyo, Japan). Five fields were randomly selected for each rat and three rats from each group were examined; therefore, a total of 15 fields were analyzed for each group. Proliferating myofibroblasts or infiltrating macrophages/macrophages were also counted using the same method. Silver staining was performed for semi-quantitative evaluation of fibroproliferative changes. The red-stained area in the silver-stained sections was exhibited on a charge-coupled device (CCD)-camera screen (magnification, x400; Keyence Corp., Osaka, Japan), and the percentage of red-stained area in each field (area, ~240x320 μm) was calculated using image analyzing software (Lumina Vision and Mac Scope, Mitani Co., Ltd., Tokyo, Japan).

**Statistical analysis.** A total of 15 fields (randomly selected as described above) were analyzed for each group. Statistical analysis of differences was performed using unpaired Student’s t-test. P<0.01 was considered to indicate a statistically significant difference.

**Results**

**Histopathology results.** There were no notable changes in the H&E stained lung sections in rats in the C group. In the lung sections from the R group, widespread distortion of the architecture with thickening of the alveolar wall and interstitium, and infiltration of mononuclear cells were observed, which suggests the presence of inflammatory and fibroproliferative change. The same findings noted in the R group were observed in lung sections from the R + T group, but the severity of these changes in the R + T group was reduced when compared with that of the R group (Fig. 2).

**TGF-β expression, myofibroblast proliferation and immune cell infiltration.** The numbers of TGF-β-expressing cells within a field in the C, R and R + T groups were 0.5±0.7, 16.7±6.5 and 8.0±2.9 [mean ± standard deviation (SD)], respectively (Fig. 3A). No marked differences regarding TGF-β expression were observed in the lungs of the C group, and definitive
TGF-β expression was observed in the lungs of the R group. By contrast, in the lungs of the R + T group, TGF-β expression was significantly lower than in the R group (Fig. 3B). The numbers of proliferating myofibroblasts within a field in the C, R and R + T groups were 1.1±1.3, 12.7±9.8 and 3.5±2.9 (mean ± SD), respectively (Fig. 4). The numbers of infiltrating macrophages/monocytes within a field in the C, R and R + T groups were 2.0±1.7, 9.5±4.4 and 4.1±4.0 (mean ± SD), respectively (Fig. 5). The findings for myofibroblast proliferation and macrophage/monocyte infiltration were identical to those for TGF-β expression in the lungs of each group. With respect to fibroproliferation, 4.5±1.0% (mean ± SD) of the total area of
NISHIOKA et al: REDUCTION OF FIBROPROLIFERATIVE CHANGES WITH TGF-β RECEPTOR

Discussion

For the management of radiation-induced fibroproliferative changes, numerous drugs have been investigated in experimental studies and clinical trials. These include anti-inflammatory agents, such as steroids, drugs acting on blood flow, interferons and superoxide dismutases (SODs). A number of these were found to be effective for the prevention and treatment of radiation-induced fibroproliferation. Using a porcine model, Lefaix et al (10) demonstrated that pentoxifylline combined with α-tocopherol is effective for the treatment of fibrotic scar tissue development following exposure to γ-rays. Delanian et al (11) revealed that liposomal Cu/Zn SOD is clinically effective in reducing long-standing radiation-induced fibrosis. Lefaix et al (12) also reported the effectiveness of Cu/Zn- or Mn-SOD for the reduction of radiation-induced fibrosis in pigs. Gauter-Fleckenstein et al (13) identified that Mn porphyrin [MnTE-2-PyP(5+)] was able to reverse lung damage when treatment was initiated 8 weeks post-irradiation, at the time of lung injury establishment, with thickening of the alveolar wall and interstitium, and infiltration of mononuclear cells.

Based on the recent findings on the molecular mechanisms of radiation-induced fibroproliferation, a number of attempts have also been made to prevent radiation-induced fibroproliferative changes in the lung via direct inhibition of TGF-β function. Rabbani et al (14) demonstrated the ability of adenovirus-mediated soluble TGF-β receptor gene therapy in preventing radiation-induced lung injury. As mentioned above, the usefulness of adenovirus-mediated soluble TGF-β type II receptor to ameliorate active TGF-β expression and to prevent radiation-induced pulmonary fibroproliferation was also reported (7). Anscher et al (15,16) demonstrated that the anti-TGF-β antibody or small molecular inhibitor of TGF-β ameliorates radiation-induced lung injury. To date, however, few attempts have been made to reduce established pulmonary fibroproliferative changes by radiation via direct inhibition of TGF-β function.
In the present study, it was demonstrated that TGF-β expression, myofibroblast proliferation, macrophage/microcyte infiltration and fibroproliferation in the irradiated lungs of rats were markedly elevated at 16 weeks following irradiation. It was also demonstrated that these markers were significantly reduced by treatment with an adenoviral vector (AdTGF-β-ExR) expressing a soluble TGF-β type II receptor at 8 weeks following irradiation, when marked TGF-β expression, myofibroblast proliferation, macrophage/microcyte infiltration and fibroproliferation were observed in 30-Gy irradiated lungs in the control rats. The present data indicates that TGF-β has a critical role in the fibroproliferative changes in the irradiated lung, and that the fibroproliferative changes induced by radiation may be reversible. The present results suggest that gene therapy with an adenoviral vector expressing a soluble TGF-β receptor is effective in reducing the established pulmonary fibrosis caused by radiation.

However, the present study only confirmed the ability of the adenovirus-mediated soluble TGF-β receptor to reduce radiation-induced pulmonary fibroproliferation at a histopathological level. Therefore, whether direct inhibition of TGF-β functions by an adenovirus-mediated soluble TGF-β receptor actually preserves respiratory function in irradiated lungs requires further investigation. In addition, although it was confirmed that the adenoviral vector itself does not affect the general condition, behavior or macroscopic appearance of the vital organs for at least three months following injection, possible long-term side-effects of TGF-β inhibition, such as carcinogenesis, should also be carefully examined in future studies. If AdTGF-β-ExR is to be used in gene therapy, efforts to optimize administration methods and to minimize side effects directly associated with the use of adenoviral vectors are also required (17).

References